相似文献
1
Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.
J Immunol Res. 2014;2014:103780. doi: 10.1155/2014/103780. Epub 2014 Jan 19.
2
β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway.
J Immunol. 2011 Apr 1;186(7):4443-54. doi: 10.4049/jimmunol.1002449. Epub 2011 Feb 18.
3
Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies.
J Neuroimmune Pharmacol. 2020 Mar;15(1):74-81. doi: 10.1007/s11481-018-09831-0. Epub 2019 Jan 7.
4
The β2-adrenergic receptor-ROS signaling axis: An overlooked component of β2AR function?
Biochem Pharmacol. 2020 Jan;171:113690. doi: 10.1016/j.bcp.2019.113690. Epub 2019 Nov 5.
5
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorg Med Chem. 2016 Jun 15;24(12):2641-53. doi: 10.1016/j.bmc.2016.04.028. Epub 2016 Apr 19.
6
β2-Adrenergic Receptors Chaperone Trapped Bitter Taste Receptor 14 to the Cell Surface as a Heterodimer and Exert Unidirectional Desensitization of Taste Receptor Function.
J Biol Chem. 2016 Aug 19;291(34):17616-28. doi: 10.1074/jbc.M116.722736. Epub 2016 Jun 24.
7
Activation of β adrenergic receptor signaling modulates inflammation: a target limiting the progression of kidney diseases.
Arch Pharm Res. 2021 Jan;44(1):49-62. doi: 10.1007/s12272-020-01280-9. Epub 2020 Nov 5.
8
β2-Adrenergics in hypoxia desensitize receptors but blunt inhibition of reabsorption in rat lungs.
Am J Respir Cell Mol Biol. 2011 Nov;45(5):1059-68. doi: 10.1165/rcmb.2010-0273OC. Epub 2011 May 11.
9
Development and characterization of pepducins as Gs-biased allosteric agonists.
J Biol Chem. 2014 Dec 26;289(52):35668-84. doi: 10.1074/jbc.M114.618819. Epub 2014 Nov 13.
10
CHIP-MYTH: a novel interactive proteomics method for the assessment of agonist-dependent interactions of the human β₂-adrenergic receptor.
Biochem Biophys Res Commun. 2014 Mar 21;445(4):746-56. doi: 10.1016/j.bbrc.2014.02.033. Epub 2014 Feb 19.
引用本文的文献
1
Implication of Central β Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease.
Arch Pharm (Weinheim). 2025 Apr;358(4):e2400750. doi: 10.1002/ardp.202400750.
2
Genome-wide association study meta-analysis of neurofilament light (NfL) levels in blood reveals novel loci related to neurodegeneration.
Commun Biol. 2024 Sep 9;7(1):1103. doi: 10.1038/s42003-024-06804-3.
3
Beta-Adrenergic Suppression of Neuroinflammation in Treatment of Parkinsonism, with Relevance for Neurodegenerative and Neoplastic Disorders.
Biomedicines. 2024 Aug 1;12(8):1720. doi: 10.3390/biomedicines12081720.
4
Neuroprotective actions of norepinephrine in neurological diseases.
Pflugers Arch. 2024 Nov;476(11):1703-1725. doi: 10.1007/s00424-024-02999-w. Epub 2024 Aug 13.
5
Formoterol Acting via β2-Adrenoreceptor Restores Mitochondrial Dysfunction Caused by Parkinson's Disease-Related UQCRC1 Mutation and Improves Mitochondrial Homeostasis Including Dynamic and Transport.
Biology (Basel). 2024 Mar 30;13(4):231. doi: 10.3390/biology13040231.
6
Beta-Blockers and Their Current Role in Maternal and Neonatal Health: A Narrative Review of the Literature.
Cureus. 2023 Aug 24;15(8):e44043. doi: 10.7759/cureus.44043. eCollection 2023 Aug.
7
Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease.
Handb Exp Pharmacol. 2024;285:555-616. doi: 10.1007/164_2023_677.
8
Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease.
Parkinsonism Relat Disord. 2023 May;110:105389. doi: 10.1016/j.parkreldis.2023.105389. Epub 2023 Mar 31.
9
Identification of a novel gene signature in second-trimester amniotic fluid for the prediction of preterm birth.
Sci Rep. 2022 Mar 31;12(1):3085. doi: 10.1038/s41598-021-04709-3.
10
Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease.
Front Aging Neurosci. 2021 Nov 16;13:768156. doi: 10.3389/fnagi.2021.768156. eCollection 2021.
本文引用的文献
1
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64. doi: 10.1136/jnnp-2013-305277. Epub 2013 Jun 18.
2
Targeting of TAK1 in inflammatory disorders and cancer.
Trends Pharmacol Sci. 2012 Oct;33(10):522-30. doi: 10.1016/j.tips.2012.06.007. Epub 2012 Jul 12.
3
β2 adrenergic-mediated reduction of blood glutamate levels and improved neurological outcome after traumatic brain injury in rats.
J Neurosurg Anesthesiol. 2012 Jan;24(1):30-8. doi: 10.1097/ANA.0b013e318232deaa.
4
Noradrenaline increases neural precursor cells derived from adult rat dentate gyrus through β2 receptor.
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):44-51. doi: 10.1016/j.pnpbp.2011.08.019. Epub 2011 Sep 5.
5
Milestones in Parkinson's disease therapeutics.
Mov Disord. 2011 May;26(6):1072-82. doi: 10.1002/mds.23714.
6
β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway.
J Immunol. 2011 Apr 1;186(7):4443-54. doi: 10.4049/jimmunol.1002449. Epub 2011 Feb 18.
7
β-arrestin Kurtz inhibits MAPK and Toll signalling in Drosophila development.
EMBO J. 2010 Oct 6;29(19):3222-35. doi: 10.1038/emboj.2010.202. Epub 2010 Aug 27.
8
beta2 Adrenergic receptor activation induces microglial NADPH oxidase activation and dopaminergic neurotoxicity through an ERK-dependent/protein kinase A-independent pathway.
Glia. 2009 Nov 15;57(15):1600-9. doi: 10.1002/glia.20873.
9
The effects of beta-adrenoceptor antagonists on proinflammatory cytokine concentrations after subarachnoid hemorrhage in rats.
Anesth Analg. 2009 Jan;108(1):288-95. doi: 10.1213/ane.0b013e318187bb93.
10
Targeting beta2-adrenoceptors for neuroprotection after cerebral ischemia: is inhibition or stimulation best?
Anesth Analg. 2009 Jan;108(1):3-5. doi: 10.1213/ane.0b013e31818db6f6.
Zotero 插件
